Drugs / XS228
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06976229 | Jul 2025 → Feb 2028 expected | spinal cord injury | XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06974968 Comparator | May 2028 → May 2031 expected | spinal cord injury | XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XS228 | “XS228 Cell Injection is an investigational, allogeneic cell therapy product composed of motor neuron progenitor cells (MNPCs) derived from human induced pluripotent stem cells (iPSCs).” NCT06974968 ↗1“XS228 is an investigational, allogeneic cell therapy product composed of motor neuron progenitor cells (MNPCs) derived from human induced pluripotent stem cells (iPSCs).” NCT06976229 ↗ |
| Known as | XS228 Cell Injection | “XS228 Cell Injection is an investigational, allogeneic cell therapy product composed of motor neuron progenitor cells (MNPCs) derived from human induced pluripotent stem cells (iPSCs).” NCT06974968 ↗ |
| Modality | Cell therapy | “allogeneic cell therapy product” NCT06974968 ↗ |
| Route | Intrathecal | “intrathecal administration” NCT06974968 ↗ |